This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Our Friends support allow the CNIO to hire more scientists and open new research lines to understand cancer better, diagnose and treat it effectively… Here are some of them!
María Moreno PhD: University of Bordeaux, France
"I study the three-dimensional structure of CAD, a protein that is highly expressed in cancer." María analyses how genetic mutations affect the structure of this protein, to develop new therapies for treatment.
"I study the three-dimensional structure of CAD, a protein that is highly expressed in cancer." María analyses how genetic mutations affect the structure of this protein, to develop new therapies for treatment.
Sarita Saraswati PhD: University of Delhi, India
"I study the role of telomere dysfunction in the origin of kidney and liver fibrosis, which in its advanced stages may lead to cancer in these organs." Sarita’s goal is to find new therapies for the treatment of these diseases.
"I study the role of telomere dysfunction in the origin of kidney and liver fibrosis, which in its advanced stages may lead to cancer in these organs." Sarita’s goal is to find new therapies for the treatment of these diseases.
Rubén Martínez PhD: University College London, UK
"I investigate how RET oncogene activity is altered in certain cancer types, such as lung and breast cancer, as well as neuroblastoma." Rubén aims to find compounds capable of inhibiting this gene that could provide more effective treatments against these types of tumours.
"I investigate how RET oncogene activity is altered in certain cancer types, such as lung and breast cancer, as well as neuroblastoma." Rubén aims to find compounds capable of inhibiting this gene that could provide more effective treatments against these types of tumours.
Rebeca Jimeno PhD: Complutense University of Madrid, Spain
"I investigate the potential of immunology as a strategy against breast cancer, specifically in Triple Negative tumors (TNBC) for a better understanding of its evolution”. Rebeca’s research aims to identify treatments targeted to the tumor with fewer side effects than current therapies.
"I investigate the potential of immunology as a strategy against breast cancer, specifically in Triple Negative tumors (TNBC) for a better understanding of its evolution”. Rebeca’s research aims to identify treatments targeted to the tumor with fewer side effects than current therapies.
Elena Fueyo Pre-Doctoral Researcher
Investigo cómo funcionan los "disfraces" y "frenos" moleculares que hacen que las células tumorales se escapen del sistema inmune. Comprender la biología de estos mecanismos es fundamental para el desarrollo de futuras inmunoterapias efectivas contra el cáncer.
Investigo cómo funcionan los "disfraces" y "frenos" moleculares que hacen que las células tumorales se escapen del sistema inmune. Comprender la biología de estos mecanismos es fundamental para el desarrollo de futuras inmunoterapias efectivas contra el cáncer.
Moustafa Ahmed Shehata Pre-Doctoral Researcher
"I study how the RET protein works, as it plays an important role in neuroblastoma, a type of fatal childhood cancer (15%) that affects the cells of the adrenal gland and the peripheral nervous system." Moustafa investigates personalised therapeutic strategies in the treatment of this aggressive tumor.
"I study how the RET protein works, as it plays an important role in neuroblastoma, a type of fatal childhood cancer (15%) that affects the cells of the adrenal gland and the peripheral nervous system." Moustafa investigates personalised therapeutic strategies in the treatment of this aggressive tumor.
Previous ‘CNIO Friends’ contracts
Neibla Priego PhD: Universidad Complutense de Madrid, Spain
"I explore therapeutic and diagnostic options for brain metastasis." These metastases arise in 10-40% of all cancer cases originating from different organs. Neibla is the first author of a study that describes how a compound called silibinin can reduce them.
"I explore therapeutic and diagnostic options for brain metastasis." These metastases arise in 10-40% of all cancer cases originating from different organs. Neibla is the first author of a study that describes how a compound called silibinin can reduce them.
Carolina Maestre PhD: Universidad Autónoma de Madrid, Spain
“We have identified a molecule involved in the survival of tumour cells when they divide. Our working hypothesis is that if we can manage to inhibit the action of those molecules, it should keep the tumour from spreading.” Carolina is looking closely at what could prove to be a new target for pharmacological-based cancer treatments.
“We have identified a molecule involved in the survival of tumour cells when they divide. Our working hypothesis is that if we can manage to inhibit the action of those molecules, it should keep the tumour from spreading.” Carolina is looking closely at what could prove to be a new target for pharmacological-based cancer treatments.
Irene Felipe PhD: Universidad de Sevilla, Spain (Juegaterapia Foundation Fellow)
“I study neuroblastoma, one of the most frequent tumors in children.” Irene hopes that the molecular findings and the translational aspects of the project, such as the identification of therapeutic strategies and the development of biomarkers, have their application in clinic in the near future.
“I study neuroblastoma, one of the most frequent tumors in children.” Irene hopes that the molecular findings and the translational aspects of the project, such as the identification of therapeutic strategies and the development of biomarkers, have their application in clinic in the near future.
Miguel Jiménez Alcázar PhD: University Medical Centre Hamburg-Eppendorf, Germany (Juegaterapia Foundation Fellow)
“I have undertaken a study focusing on gliomas, cerebral tumours common in children and adolescents.” Miguel’s goal is to see that the results are transferred to the clinical sphere, where they can contribute to increasing patients’ survival rates and improving the quality of life.
“I have undertaken a study focusing on gliomas, cerebral tumours common in children and adolescents.” Miguel’s goal is to see that the results are transferred to the clinical sphere, where they can contribute to increasing patients’ survival rates and improving the quality of life.
Sebastián Thompson PhD: City University of New York (CUNY), USA
“I am examining the process by which nanoparticles can be used to transport medication to a specific location in the body, on account of their enhanced ability to reach the compromised cells.” Sebastián’s work involves searching for the best way to make certain that the greatest possible number of nanoparticles actually make it all the way to the tumour location.
“I am examining the process by which nanoparticles can be used to transport medication to a specific location in the body, on account of their enhanced ability to reach the compromised cells.” Sebastián’s work involves searching for the best way to make certain that the greatest possible number of nanoparticles actually make it all the way to the tumour location.